Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
Bo Hu(Union Hospital), Shengyuan Yu(Chinese PLA General Hospital), Xiang Li(Shandong University), Gang Li(Southwest University), Xiaohong Li(Shandong University), Junpeng Zhuang(Lilly (China)), Hongru Zhao(Soochow University), Zhihua Jia(Chinese PLA General Hospital), Shan Wu(Jilin University), Tingmin Yu(Second Affiliated Hospital of Jilin University)
Cited by 37
Related Papers
Microglia-derived TNF-α mediates endothelial necroptosis aggravating blood brain–barrier disruption after ischemic stroke
|Cell Death and Disease|2019|551
China stroke surveillance report 2021
|Military Medical Research|2023|525
LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation
|Cell Death and Disease|2019|207
Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke
|New England Journal of Medicine|2024|162
Cardiovascular Diseases and Risk‐Factor Burden in Urban and Rural Communities in High‐, Middle‐, and Low‐Income Regions of China: A Large Community‐Based Epidemiological Study
|Journal of the American Heart Association|2017|113